SCHEMBL2302737

SCHEMBL2302737

CN(C)OP(=O)(OCl)OCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11882765 0.94
SCHEMBL9319092 0.81 TSHR (0.30)
SCHEMBL28270141 0.72
SCHEMBL11778510 0.71
SCHEMBL7585 0.69
SCHEMBL180621 0.69 TP53 (0.30)
SCHEMBL2302735 0.69
SCHEMBL27471897 0.67
SCHEMBL6233086 0.67
SCHEMBL28495934 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10905782-B2 Compositions for enhancing transport of molecules into cells SAREPTA THERAPEUTICS, INC. (US) 2021-02-02 US disclosed
US-10300149-B2 Compositions for enhancing transport of molecules into cells SAREPTA THERAPEUTICS, INC. (US) 2019-05-28 US disclosed
US-20170368203-A1 Compositions For Enhancing Transport Of Molecules Into Cells SAREPTA THERAPEUTICS, INC. 2017-12-28 US disclosed
US-9572899-B2 Compositions for enhancing transport of molecules into cells AVI BIOPHARMA, INC. (US) 2017-02-21 US disclosed
EP-2351844-B1 COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS SAREPTA THERAPEUTICS INC (US) 2014-06-11 EP disclosed
EP-2351844-A1 Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells AVI BioPharma, Inc. (US) 2011-08-03 EP disclosed
EP-1629105-B1 COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS AVI BIOPHARMA INC (US) 2010-09-01 EP disclosed
US-20090082547-A1 COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO CELLS SAREPTA THERAPEUTICS, INC. 2009-03-26 US disclosed
US-7468418-B2 peptide nucleic acid conjugate of a nucleic acid analog covalently linked to a peptide transporter moiety; enhance antisense activity; drug delivery; conjugate is a morpholino-base with phosphorodiamidate linkages with a peptide such as Arg9Phe2 (arginine9phenylalanine2) AVI BIOPHARMA., INC. (US) 2008-12-23 US disclosed
EP-1629105-A2 COMPOSITIONS FOR ENHANCING TRANSPORT AND ANTISENSE EFFICACY OF NUCLEIC ACID ANALOG INTO CELLS Avi Biopharma, Inc. (US) 2006-03-01 EP disclosed
US-5378841-A Alpha-morpholino ribonucleoside derivatives and polymers thereof ANTIVIRALS INC. (US) 1995-01-03 US disclosed
WO-1994012517-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1994-06-09 WO disclosed
EP-0592511-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS. ANTIVIRALS INC (US) 1994-04-20 EP disclosed
US-5235033-A ALPHA-MORPHOLINO RIBONUCLEOSIDE DERIVATIVES AND POLYMERS THEREOF ANTI-GENE DEVELOPMENT GROUP (US) 1993-08-10 US disclosed
US-5185444-A Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages ANTI-GENE DEVEOPMENT GROUP (US) 1993-02-09 US disclosed
WO-1993000352-A1 SEQUENCE-SPECIFIC BINDING POLYMERS FOR DUPLEX NUCLEIC ACIDS ANTIVIRALS INC. (US) 1993-01-07 WO disclosed
EP-0506830-A4 UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES 1993-01-07 EP disclosed
US-5166315-A Polynucleotides for genetic engineering ANTI-GENE DEVELOPMENT GROUP (US) 1992-11-24 US disclosed
EP-0506830-A1 UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES ANTIVIRALS INC. (US) 1992-10-07 EP disclosed
WO-1991009033-A1 UNCHARGED MORPHOLINO-BASED POLYMERS HAVING PHOSPHOROUS-CONTAINING CHIRAL INTERSUBUNIT LINKAGES ANTI-GENE DEVELOPMENT GROUP (US) 1991-06-27 WO disclosed